Literature DB >> 1690891

Association of the v-crk oncogene product with phosphotyrosine-containing proteins and protein kinase activity.

B J Mayer1, H Hanafusa.   

Abstract

An antiserum specific for P47gag-crk, the oncogene product of avian sarcoma virus CT10, was used to investigate possible crk-binding proteins. In in vitro kinase assays, four proteins were phosphorylated in anti-crk immunoprecipitates. Tyrosine, serine, and threonine residues were phosphorylated. A number of tyrosine-phosphorylated proteins were identified in anti-crk immunoprecipitates of 32P-labeled cells, including the three major phosphotyrosine-containing proteins of CT10-infected cells. These three proteins also bound to bacterially synthesized crk protein. These results suggest that the crk transforming protein can stably associate with both endogenous kinases and cellular kinase substrates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690891      PMCID: PMC53745          DOI: 10.1073/pnas.87.7.2638

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Isolation of antibodies for phosphotyrosine by immunization with a v-abl oncogene-encoded protein.

Authors:  J Y Wang
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

2.  Platelet-derived growth factor induces rapid and sustained tyrosine phosphorylation of phospholipase C-gamma in quiescent BALB/c 3T3 cells.

Authors:  M I Wahl; N E Olashaw; S Nishibe; S G Rhee; W J Pledger; G Carpenter
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

3.  Direct activation of the serine/threonine kinase activity of Raf-1 through tyrosine phosphorylation by the PDGF beta-receptor.

Authors:  D K Morrison; D R Kaplan; J A Escobedo; U R Rapp; T M Roberts; L T Williams
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

4.  Phospholipase C-gamma is a substrate for the PDGF and EGF receptor protein-tyrosine kinases in vivo and in vitro.

Authors:  J Meisenhelder; P G Suh; S G Rhee; T Hunter
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

5.  Stable association of activated pp60src with two tyrosine-phosphorylated cellular proteins.

Authors:  A B Reynolds; S B Kanner; H C Wang; J T Parsons
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

6.  EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling.

Authors:  B Margolis; S G Rhee; S Felder; M Mervic; R Lyall; A Levitzki; A Ullrich; A Zilberstein; J Schlessinger
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

7.  A second type of rat phosphoinositide-specific phospholipase C containing a src-related sequence not essential for phosphoinositide-hydrolyzing activity.

Authors:  Y Emori; Y Homma; H Sorimachi; H Kawasaki; O Nakanishi; K Suzuki; T Takenawa
Journal:  J Biol Chem       Date:  1989-12-25       Impact factor: 5.157

8.  Detection of phosphotyrosine-containing proteins in polyomavirus middle tumor antigen-transformed cells after treatment with a phosphotyrosine phosphatase inhibitor.

Authors:  W Yonemoto; A J Filson; A E Queral-Lustig; J Y Wang; J S Brugge
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

9.  N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.

Authors:  P Jackson; D Baltimore
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

10.  Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation.

Authors:  S A Courtneidge
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

View more
  61 in total

1.  Src homology region 2 domains direct protein-protein interactions in signal transduction.

Authors:  M F Moran; C A Koch; D Anderson; C Ellis; L England; G S Martin; T Pawson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Purification and characterization of a phosphatidylinositol 3-kinase complex from bovine brain by using phosphopeptide affinity columns.

Authors:  M J Fry; G Panayotou; R Dhand; F Ruiz-Larrea; I Gout; O Nguyen; S A Courtneidge; M D Waterfield
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

3.  Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences.

Authors:  R J Matthews; D B Bowne; E Flores; M L Thomas
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

4.  Biological and biochemical activity of v-Crk chimeras containing the SH2/SH3 regions of phosphatidylinositol-specific phospholipase C-gamma and Src.

Authors:  M Matsuda; C T Reichman; H Hanafusa
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo.

Authors:  B J Mayer; P K Jackson; R A Van Etten; D Baltimore
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

6.  The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors.

Authors:  W Li; P Hu; E Y Skolnik; A Ullrich; J Schlessinger
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

7.  The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor.

Authors:  A Klippel; J A Escobedo; W J Fantl; L T Williams
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

8.  Multiple SH2-mediated interactions in v-src-transformed cells.

Authors:  C A Koch; M F Moran; D Anderson; X Q Liu; G Mbamalu; T Pawson
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts.

Authors:  R B Birge; J E Fajardo; C Reichman; S E Shoelson; Z Songyang; L C Cantley; H Hanafusa
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

10.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.